Phoenix—When approved for use in the
United States in 1996, tissue-type plasminogen activator (tPA) was hailed
by many as a revolutionary breakthrough for the treatment of ischemic stroke. But now, almost seven years later, the use of this
thrombolytic agent is at the center of an ongoing debate between proponents
who say tPA use remains frustratingly low and the emergency physicians who
are faced with treatment decisions in real-world settings.
Mitka M. Tensions Remain Over tPA for Stroke. JAMA. 2003;289(11):1363–1364. doi:10.1001/jama.289.11.1363
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: